Van LanckerLPetrarcaRMoutsourisKMasaoutisPKampougerisGClinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.Eur J Ophthalmol201650008610
2.
GroverSMurthyRKBrarVSChalamKVNormative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis).Am J Ophthalmol2009148(2)266–271
3.
Schmidt-ErfurthUKaiserPKKorobelnikJFet al.Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.Ophthalmology2014121(1)193–201
4.
JaffeGJKaiserPKThompsonDet al.Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid.Ophthalmology2016123(9)1856–1864
5.
PapadopoulosNMartinJRuanQet al.Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.Angiogenesis201215(2)171–185
